Meningococcal (Serogroup A) Polysaccharide 10 ug, Meningococcal (Serogroup C) Polysaccharide 10 ug, Meningococcal (Serogroup Y) Polysaccharide 10 ug, Meningococcal (Serogroup W135) Polysaccharide 10 ug
الاستخدامات الطبية المعتمدة
MenQuadfi is indicated for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
Malignant pleural mesothelioma
Pemetrexed Disodium in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer
Pemetrexed Disodium in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Pemetrexed Disodium is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
Pemetrexed Disodium is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:
• Mantle Cell Lymphoma
Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
• Acute Lymphoblastic Leukemia
Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:
• Mantle Cell Lymphoma
Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
• Acute Lymphoblastic Leukemia
Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Treatment of essential hypertension.
is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
Treatment of essential hypertension.
is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
Treatment of essential hypertension.
is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
